Two small IPOs and two SPACs debuted this past week - Global Engine, Kairos Pharma, YHN Acquisition I, and Cayson Acquisition ...

The Fed cut the Fed funds target rate by 0.50 percent, and for maybe the first time in this entire monetary policy cycle, the ...

The US stock markets opened lower on Friday, September 20, as investors held back after a jump in the previous session, which ...

Corbus Pharmaceuticals Holdings Inc. closed $42.39 short of its 52-week high ($61.90), which the company reached on July 31st ...

The best performers of the session on the Dow Jones Industrial Average were Nike Inc (NYSE: NKE ), which rose 6.84% or 5.54 ...

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...

Shares of Novo Nordisk A/S fell after the Danish drugmaker reported mixed safety data on one of its next-generation ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...